Vnitr Lek 1997, 43(10):639-644

[The autoantibody profile and disease activity in patients with systemic lupus erythematosus].

P Horák, Z Hermanová, L Faltýnek, Z Pospísil, V Scudla
III. interní klinika LF UP a FN, Olomouc.

Klíčová slova: Adolescent; Adult; Aged; Antibodies, Antinuclear, analysis, ; Autoantibodies, analysis, ; Female; Humans; Lupus Erythematosus, Systemic, diagnosis, ; Male; Middle Aged

Antinuclear antibodies are a group of autoantibodies which are typical for collagenous diseases. By means of the autoantibody profile different sub-groups of systemic lupus erythematosus (SLE) can be identified. This can serve as a certain prognostic factor of the affection. Patients with a negative antibody profile have fewer clinical and laboratory manifestations of SLE. Profile A (anti-dsDNA and/or anti-Sm has, as compared with patients with a negative antibody profile, more frequent organ manifestations. Patients with profile B (anti-RNP) have a higher frequency of Raynaud's phenomenon. Profile C (anti-Ro, anti-La) is characterized in particular by photosensitivity of the skin and secondary Sjögren's syndrome. Profile D (antibodies against centromeres and/or Scl-70) are found in subjects with SLE with traits of scleroderma. Finally profile E (antibodies against histones) are found in SLE induced by drugs. In the submitted study in 28 patients with SLE autoantibodies anti-dsDNA, anti-DNP, extracted nuclear antibodies (ENA-Sm,Ro,La, histones, Sm/RNP, Scl-70) were evaluated and different subgroups of SLE were assessed. Attention was paid to their common characteristics and the activity of the disease. Associations of clinical activity of the disease expressed by the ECLAM index (European Consensus Lupus Activity Measurement) were tested as well as anti-dsDNA levels and also the association of the disease activity with C3 and C4 constituents of complement, CRP and circulating immunocomplexes in serum. Positivity of the antinuclear factor (ANF) was found in 21 patients, while in 7 subjects who were in clinical and laboratory remission, ANF was negative. A negative antibody profile was recorded in 9 patients, profile A was found in 13, 1 patient had profile B, and 4 patients had profile C. Antibody profile D was not found in the group. When using regression analysis and Pearson s correlation coefficient, correlations were found between anti-dsDNA values and the system ECLAM (r = 0.72, p < 0.01), anti-dsDNA and C3 levels (r = -0.59, p < 0.01), C4 (r = -0.50,, p < 0.01), and between the ECLAM system and C3 (r = -0.60, p 0.01) and C4 (r = -0.52, p < 0.01) and also between C3 and C4 mutually (r = 0.72, p < 0.01). From the submitted investigation ensues that investigation of antinuclear antibody levels in SLE is important not only for assessment of the diagnosis of the disease and its activity but also for assessment of the subgroups of the disease and for prediction of its development. As to other indicators of activity, assessment of the C3 and C4 constituents of complement is still important.

Keywords: Adolescent; Adult; Aged; Antibodies, Antinuclear /analysis/; Autoantibodies /analysis/; Female; Humans; Lupus Erythematosus, Systemic /diagnosis/; Male; Middle Aged

Zveřejněno: 1. říjen 1997  Zobrazit citaci

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horák P, Hermanová Z, Faltýnek L, Pospísil Z, Scudla V. [The autoantibody profile and disease activity in patients with systemic lupus erythematosus]. Vnitr Lek. 1997;43(10):639-644.
Stáhnout citaci




Vnitřní lékařství

Vážená paní, pane,
upozorňujeme Vás, že webové stránky, na které hodláte vstoupit, nejsou určeny široké veřejnosti, neboť obsahují odborné informace o léčivých přípravcích, včetně reklamních sdělení, vztahující se k léčivým přípravkům. Tyto informace a sdělení jsou určena výhradně odborníkům dle §2a zákona č.40/1995 Sb., tedy osobám oprávněným léčivé přípravky předepisovat nebo vydávat (dále jen odborník).
Vezměte v potaz, že nejste-li odborník, vystavujete se riziku ohrožení svého zdraví, popřípadě i zdraví dalších osob, pokud byste získané informace nesprávně pochopil(a) či interpretoval(a), a to zejména reklamní sdělení, která mohou být součástí těchto stránek, či je využil(a) pro stanovení vlastní diagnózy nebo léčebného postupu, ať už ve vztahu k sobě osobně nebo ve vztahu k dalším osobám.

Prohlašuji:

  1. že jsem se s výše uvedeným poučením seznámil(a),
  2. že jsem odborníkem ve smyslu zákona č.40/1995 Sb. o regulaci reklamy v platném znění a jsem si vědom(a) rizik, kterým by se jiná osoba než odborník vstupem na tyto stránky vystavovala.


Ne

Ano

Pokud vaše prohlášení není pravdivé, upozorňujeme Vás,
že se vystavujete riziku ohrožení svého zdraví, popřípadě i zdraví dalších osob.